WO1998015638A3 - Replication-defective adenoviruses for cancer immunotherapy - Google Patents

Replication-defective adenoviruses for cancer immunotherapy Download PDF

Info

Publication number
WO1998015638A3
WO1998015638A3 PCT/US1997/017948 US9717948W WO9815638A3 WO 1998015638 A3 WO1998015638 A3 WO 1998015638A3 US 9717948 W US9717948 W US 9717948W WO 9815638 A3 WO9815638 A3 WO 9815638A3
Authority
WO
WIPO (PCT)
Prior art keywords
replication
tumor rejection
cancer immunotherapy
methods
defective adenoviruses
Prior art date
Application number
PCT/US1997/017948
Other languages
French (fr)
Other versions
WO1998015638A2 (en
WO1998015638B1 (en
Inventor
Darryl S Reed
Pedro Romero
Donata Rimoldi
Jean-Charles Cerrottini
C Victor Jongeneel
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Priority to AU46687/97A priority Critical patent/AU4668797A/en
Publication of WO1998015638A2 publication Critical patent/WO1998015638A2/en
Publication of WO1998015638A3 publication Critical patent/WO1998015638A3/en
Publication of WO1998015638B1 publication Critical patent/WO1998015638B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides compositions and methods for using replication-deflective adenoviruses and adenovirus genomes to introduce nucleic acids encoding tumor rejection antigen precursors into cells. The compositions and methods are useful for, inter alia, inducing or enhancing by in vivo or ex vivo means the immune response of a subject to tumor rejection antigens, preparation of cytolytic T lymphocytes and analysis of tumor rejection antigen precursor processing.
PCT/US1997/017948 1996-10-07 1997-10-06 Replication-defective adenoviruses for cancer immunotherapy WO1998015638A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU46687/97A AU4668797A (en) 1996-10-07 1997-10-06 Replication-defective adenoviruses for cancer immunotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2789196P 1996-10-07 1996-10-07
US60/027,891 1996-10-07

Publications (3)

Publication Number Publication Date
WO1998015638A2 WO1998015638A2 (en) 1998-04-16
WO1998015638A3 true WO1998015638A3 (en) 1998-07-02
WO1998015638B1 WO1998015638B1 (en) 1998-08-13

Family

ID=21840363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/017948 WO1998015638A2 (en) 1996-10-07 1997-10-06 Replication-defective adenoviruses for cancer immunotherapy

Country Status (3)

Country Link
AU (1) AU4668797A (en)
WO (1) WO1998015638A2 (en)
ZA (1) ZA978959B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016320A1 (en) * 1999-08-30 2001-03-08 Ludwig Institute For Cancer Research Isolated nona and decapeptides which bind to hla molecules, and the use thereof
US6756044B1 (en) 2000-02-09 2004-06-29 Genvec, Inc. Antigenic complexes and methods
EP2412792A1 (en) 2010-07-29 2012-02-01 The Procter & Gamble Company Liquid detergent composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016713A1 (en) * 1993-01-22 1994-08-04 Ludwig Institute For Cancer Research Method for identifying and treating individuals bearing cancer cells that express hla-c-clone 10/mage-1
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1997034009A1 (en) * 1996-03-14 1997-09-18 Rhone-Poulenc Rorer S.A. Recombinant adenoviral vectors for human tumour gene therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016713A1 (en) * 1993-01-22 1994-08-04 Ludwig Institute For Cancer Research Method for identifying and treating individuals bearing cancer cells that express hla-c-clone 10/mage-1
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
WO1997034009A1 (en) * 1996-03-14 1997-09-18 Rhone-Poulenc Rorer S.A. Recombinant adenoviral vectors for human tumour gene therapy

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BUEELER H ET AL: "INDUCTION OF ANTIGEN-SPECIFIC TUMOR IMMUNITY BY GENETIC AND CELLULAR VACCINES AGAINST MAGE: ENHANCED TUMOR PROTECTION BY COEXPRESSION OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND B7-1", MOLECULAR MEDICINE, vol. 2, no. 5, September 1996 (1996-09-01), pages 545 - 555, XP002035094 *
KANTOFF, P. ET AL.: "Expression of human adenosine deaminase in nonhuman primates after retrovirus-mediated gene transfer", JOURNAL OF EXPERIMENTAL MEDICIN, vol. 116, 1987, pages 219 - 234, XP002051671 *
LAUGHLIN C A ET AL: "EFFECT OF DELETIONS IN ADENOVIRUS EARLY REGION 1 GENES UPON REPLICATION OF ADENO-ASSOCIATED VIRUS", PHYSIOLOGIA PLANTARUM, vol. 41, no. 3, March 1982 (1982-03-01), pages 868 - 876, XP000614630 *
PLAEN DE E ET AL: "STRUCTURE, CHROMOSOMAL LOCALIZATION, AND EXPRESSION OF 12 GENES OF THE MAGE FAMILY", IMMUNOGENETICS, vol. 40, no. 5, 1994, pages 360 - 369, XP000614537 *
RALSTON R ET AL: "COMPARISON OF CELLULAR IMMUNITY TO MAGE TUMOR ANTIGENS ELICITED IN MICE USING PEPTIDES, PURIFIED PROTEIN, VACCINIA VIRUS, AND POLYNUCLEOTIDE VACCINES", JOURNAL OF CELLULAR BIOCHEMISTRY - SUPPLEMENT, 10 March 1995 (1995-03-10), pages 175, XP002030629 *
REED, D.S. ET AL.: "Construction and characterization of a recombinant adenovirus directing expression of the MAGE-1 tumor-specific antigen", INTERNATIONAL JOURNAL OF CANCER, vol. 72, no. 6, 17 September 1997 (1997-09-17), pages 1045 - 1055, XP002051672 *
WARNIER G ET AL: "INDUCTION OF A CYTOLYTIC T-CELL RESPONSE IN MICE WITH A RECOMBINANT ADENOVIRUS CODING FOR TUMOR ANTIGEN P815A", INTERNATIONAL JOURNAL OF CANCER, vol. 67, no. 2, 17 July 1996 (1996-07-17), pages 303 - 310, XP000675638 *
ZHAI, Y. ET AL.: "Development and characterization of recombinant adenoviruses encoding MART1 or pg100 for cancer therapy", JOURNAL OF IMMUNOLOGY, vol. 156, no. 2, 15 January 1996 (1996-01-15), pages 700 - 710, XP002036180 *

Also Published As

Publication number Publication date
WO1998015638A2 (en) 1998-04-16
AU4668797A (en) 1998-05-05
ZA978959B (en) 1998-06-23

Similar Documents

Publication Publication Date Title
Herlyn et al. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody
WO2000036107A3 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
EP2022800A3 (en) Compositions for the therapy and diagnosis of ovarian cancer
WO1999004265A8 (en) Cancer associated nucleic acids and polypeptides
WO1989001973A3 (en) Recombinant pox virus for immunization against tumor-associated antigens
BG111337A (en) Human antibodies binding human il-12 and methods for obtaining them
DK0584266T3 (en) Recombinant virus expressing carcino embryonic antigen and methods for its use
EP1335023A3 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
WO2000029428A3 (en) 5t4 tumour-associated antigen for use in tumour immunotherapy
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
CA2261989A1 (en) Recombinant pox virus for immunization against tumor-associated antigens
IL188875A0 (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
CA2336743A1 (en) Antigenic peptides derived from telomerase
WO1998033527A3 (en) Cancer immunotherapy with semi-allogeneic cells
CA2185470A1 (en) Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
IL141775A0 (en) Aglyco products and methods of use
WO1998058956A3 (en) Methods for inducing an immune response involving prime-boost protocols
CA2232344A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
WO2001021201A3 (en) Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen
WO1998015638A3 (en) Replication-defective adenoviruses for cancer immunotherapy
MXPA01003240A (en) Mammaglobin, a secreted mammary-specific breast cancer protein.
WO1998039027A3 (en) Sialyl lewis antigens as targets for immunotherapy
Zbar et al. Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target.
Wagner Antitumor antibodies for immunotherapy of ovarian carcinomas

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP KR NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP KR NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 15/98 UNDER (30) "06.10.96" BY "07.10.96"

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase